1. Home
  2. ICUI vs RCUS Comparison

ICUI vs RCUS Comparison

Compare ICUI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$180.72

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$30.37

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICUI
RCUS
Founded
1984
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
3.8B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
ICUI
RCUS
Price
$180.72
$30.37
Analyst Decision
Strong Buy
Buy
Analyst Count
3
10
Target Price
$169.00
$31.90
AVG Volume (30 Days)
299.1K
1.2M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
100.62
N/A
EPS
1.96
N/A
Revenue
$2,231,262,000.00
$247,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.46
$45.62
P/E Ratio
$92.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$112.50
$10.40
52 Week High
$192.85
$31.74

Technical Indicators

Market Signals
Indicator
ICUI
RCUS
Relative Strength Index (RSI) 61.23 59.71
Support Level $133.45 $25.94
Resistance Level $191.07 $31.41
Average True Range (ATR) 4.34 1.10
MACD -0.89 0.19
Stochastic Oscillator 28.30 78.79

Price Performance

Historical Comparison
ICUI
RCUS

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

Share on Social Networks: